Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Current Issue

Volume 12, Issue 7 (2020)

    Editor Note Pages: 1 - 0

    Editorial Note for Journal of Cancer Science and Therapy

    Shravan K. Putta

    DOI: 10.37421/jcst.2020.12.e137

    The Journals aims to flourish and to maintain the standards in research and cancer diagnosis, provide platform and opportunity to present research outcome and thus help in promoting Cancer and Oncology research and probably it is much in deed for students, teachers and health care professionals to enhance the patient care.

    Mini Review Pages: 1 - 3

    The Role of PARP Inhibitors in the Treatment of Triple Negative Breast Cancer

    Karima Oualla, Lamiae Nouiakh, Otmane Zouiten, Mohamed Ismaili, lamiae Amaadour, Zineb Benbrahim, Samia Arifi and Nawfel Mellas

    DOI: 10.37421/jcst.2020.12.636

    Triple Negative Breast Cancer (TNBC) is a particular subtype of breast cancer accounting for 15% to 20% of all breast cancer. It is defined on
    immunohistochemistry (IHC) by negative estrogen receptor (ER) and progesterone receptors (PR) and negative human epidermal growth factor
    receptor 2 (HER2) and characterized by aggressive nature, distinct metastatic patterns, lack of targeted therapies and poor outcomes. Cytotoxic
    chemotherapy was the mainstay of treatment for long decades and the development of new treatments for selected patients was complicated
    because of the heterogeneity of TNBC. The good understanding of molecular and genomic mechanisms of TNBC has allowed the development
    of new targeted therapies more efficient. Although the heterogeneity of genetic alterations in TNBCs based on the ethnicity and the age, BRCA
    mutations are found in around 20% to 25% of patients and especially in those of the basal-like immune-phenotype. Thus, targeting the defects
    in the DNA repair pathway becomes a promising field of research for this selected category of TNBC patients. Poly (ADP-ribose) polymerase
    (PARP) inhibitors exploit this DNA defects through synthetic lethality and therefore represent a promising treatment especially in BRCA1/ BRCA2
    mutation carriers. These findings have finally allowed bringing personalized treatment to this orphan disease. In this work we tried to explain the
    rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a
    new standard of care in TNBC.

    Research Article Pages: 1 - 5

    Changing Paediatric Cancer Practice in COVID-19 Times

    Rajendra B. Nerli, Abhilasha Sampagar, Manas Sharma, Shridhar C. Ghagane, Sushant Deole, Pulkit Gupta, Shashank D. Patil and Murigendra B. Hiremath

    DOI: 10.37421/jcst.2020.12.637

    Introduction: Experts dealing with the treatment of cancer in children believe that the COVID-19 pandemic could pose a serious global challenge
    to the delivery of affordable and equitable treatment to children with cancer. In this paper we report our experience in the management of children
    with cancer in these COVID-19 times.
    Patients and Methods: Out-patient case records, in-patient case records, imaging pictures of all children with cancer attending our hospital were
    retrieved and analyzed.
    Results: Our study period extended from Dec 2019 until the end of April 2020. During this period, it was observed that the number of children
    attending the outpatient department, undergoing day-care procedures including chemotherapy, as well as children undergoing surgery progressively
    declined due to COVID-19 associated lockdown. Efforts were made to help the children and their families to gain easy access to treatment.
    Conclusion: COVID-19 has disrupted the world and has caused widespread anxiety among families of children with cancer. The medical fraternity
    with active help from all agencies should work out measures to reduce these difficulties faced by children and their families to provide the means
    to ensure the continuity of curative treatments and palliative care as effectively as possible.

    Review Article Pages: 1 - 5

    A Review on Merkel Cell Polyomavirus - A Subclinical Infection or a Sinisterical Carcinogen?

    Sasi S. Senga and Jemma Arakelyan

    DOI: 10.37421/jcst.2020.12.638

    Viral infections can be attributed to a significant percentage of the global cancer burden. In this review, we will delve into the principles of the
    molecular mechanism underpinning Merkel cell polyomavirus associated oncogenesis. Merkel cell polyomavirus leads to highly aggressive and
    relatively rare skin cancer known as Merkel cell carcinoma. This virus was first detected in 2008 when it was secluded from tumors of patients with
    Merkel cell carcinoma. The presence of Merkel cell polyoma virus in tumors was confirmed by Southern blot analysis and sequencing. Of the 10
    tumors tested, 8 were positive for virus, confirming a strong association, which led to the WHO IARC classification as a Group 2A, “carcinogenic
    to humans”. There is little evidence which shows the association of Merkel cell polyomavirus and lung cancer. The plethora of diagnostic and
    predictive biomarkers that are evolving alongside therapeutic and preventive strategies for Merkel cell polyomavirus associated cancers and the
    evidence of its role in tumourigenesis.

    Commentary Pages: 1 - 3

    Electronic Nicotine Delivery Systems (ENDS) - Risk Factors and Comorbidities

    Govinda Yadav

    DOI: 10.37421/jcst.2020.12.639

    An electronic cigarette (or e-cig) is a battery-fuelled vaporizer that mirrors tobacco smoking. It works by heating up a nicotine fluid, called "juice." It
    is sold as a more beneficial interchange than conventional cigarettes. Nicotine juice (or e-juice) comes in different flavors and nicotine levels. e-fluid
    is made out of five fixings: vegetable glycerin (a material utilized in a wide range of food and individual consideration items, similar to toothpaste)
    and propylene glycol (a dissolvable most regularly utilized in mist machines.) propylene glycol is the fixing that produces thicker billows of fume.

Relevant Topics

Recommended Conferences

Cancer Meet 2020

San Francisco, USA
arrow_upward arrow_upward